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Use of Chemotherapy in Pregnant Breast Cancer Patients
Abstract
With fertility now possible at a later age, women find themselves at an increased risk for concurrent breast
cancer diagnosis. Due to the teratogenic effects of most chemotherapeutic agents, difficult decisions must be
made regarding the best outcomes for both mother and baby. Depending on the stage of their cancer, the
gestational age of the fetus, and the timing of the diagnosis, women must choose between a therapeutic
abortion, safer surgical modalities, a modified treatment plan beginning in the second or third trimester, or
postponement of the treatment until the baby is born. Oncology and OB/GYN nurses need to be aware of
these complex cases and offer advanced support and care to meet the needs of their patients.
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With fertility now possible at a later age, women find themselves at an increased risk for concurrent
breast cancer diagnosis. Due to the teratogenic effects of most chemotherapeutic agents, difficult decisions
must be made regarding the best outcomes for both mother and baby. Depending on the stage of their
cancer, the gestational age of the fetus, and the timing of the diagnosis, women must choose between a
therapeutic abortion, safer surgical modalities, a modified treatment plan beginning in the second or third
trimester, or postponement of the treatment until the baby is born. Oncology and OB/GYN nurses need to be
aware of these complex cases and offer advanced support and care to meet the needs of their patients.
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vomiting, swelling, and increased skin pigmentation,
symptoms similar to those in malignancy. A
woman's immune system can weaken naturally
during pregnancy just as pathologically cancer will
lower white bloQ,d cell counts. This endangers the
woman and her baby to various infections (Moran,
Yano, AI Zahir, & Farquharson, 2007). These
changes may complicate a cancer diagnosis
when in conjunction with an active pregnancy.
Women weigh a variety of priorities, risks,
benefits, and options to decide upon an effective
treatment. Radiation, chemotherapeutic agents,
anesthesia, and surgery create the highest risk of
birth defects in the first trimester (Moran et aI.,
2007). In this crucial stage for the developing fetus,
all possible teratogenic substances and radiotherapy
are to be avoided. "In addition, the adverse effects
of radiation are directly related to the stage of
gestation - the earlier the stage, the more detrimental
the expected effects (Pavlidis, 2002, p. 280)." The
standard of care for many stage I and stage II breast
cancer are surgical resectioning and mastectomy
(Dean, 2007). Any breast reconstruction is delayed
until delivery. Radiotherapy and chemotherapy
should be withheld to ensure the safety of the fetus.
Exposure to chemotherapy in the first trimester is
linked to spontaneous abortions, intra-uterine fetal
demise, and serious abnormalities (Cardonick &
Iacobucci, 2004). Staging scans, such as x-rays and
A new pregnancy may be an overwhelming
experience and ushers in drastic changes to a
woman's life. When pregnancy is complicated by the
occurrence of breast cancer, women, their families,
and their clinicians face difficult choices in judging
the risks and benefits oftreatment and their effects on
mother and baby alike (Dean, 2007). With fertility
becoming possible in later years ofadulthood, women
are increasingly at risk for concurrent pregnancy and
malignancy. The incidence of breast cancer is 1 in
3,000 pregnancies (Pavlidis, 2002). An ethical issue
erupts when for long term survival a pregnant woman
must balance her optimal treatment with the health
and safety of her unborn child. The teratogenic
effects of chemotherapeutic agents can negatively
affect a developing fetus during pregnancy. The
medical needs of the mother and protecting the fetus
are two conflicting priorities. With 3,500 pregnant
women diagnosed every year with various types
of cancer, nurses must be increasingly aware of
the specialized needs, support, and interventions
to provide optimal care (Pavlidis, 2002).
Context in Maternal and Fetal Health
Women may not be aware of the variations
when pregnancy and malignancy interact in the
body. An initial diagnosis of breast cancer may
be delayed 5 - 7 months in pregnant women;
breast lumps or masses are commonly attributed
to the hormonal shifts in antepartum (Dean, 2007).
Pregnancy can also account for fatigue, nausea,
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computerized tomography (CT) scans expose fetuses
to harmful ionizing radiation. Magnetic Resonance
Images's (MRI)andultrasoundsprovideasafe imaging
tool to utilize in pregnant women (Dean, 2007).
In stage III and IV cases of metastatic breast
cancer, abortion may be considered most logical
first step in a treatment plan. The existence of
metastatic disease demands that the patient receive
immediate adjuvant chemotherapy. Delaying this
treatment would result in shorter life span, shorter
time to progression, and poorer outcomes. While
therapeutic abortion would allows the patient to fully
pursue the most effective chemotherapy regimen
without worry of teratogenicity, no evidence has
been shown that a therapeutic abortion increases
survival (Epstein, 2007). "In the 1980s and 1990s,
therapeutic abortion failed to improve survival,
and it was found that pregnancy had no effect
on the course of the disease" (Pavlidis, 2002, p.
281). Therapeutic abortions are rarely advised and
only suggested in advanced breast cancer cases
diagnosed early in pregnancy (Pavlidis, 2002).
A modified chemotherapy treatment during
the second and third trimesters decreases risk to
pregnant mothers and fetuses. "Despite the fact
that all chemotherapy drugs are capable of crossing
the placenta, fetal toxicity is clearly dependent
on the time of treatment" (Pavlidis, 2002, p. 284).
Teratogenic drugs such as taxanes, vinorelbine, and
transtuzumab are avoided; however, fluorouracil,
epirubicin, cyclophosphamide, and others appear
relatively safe (Dean, 2007). Oncologists who
prescribe "gestational chemotherapy" for pregnant
women with breast cancer, find that anthracycline-
based treatment results in "minimal complications
of labor and delivery" and "minimal risk to the
fetus" (Epstein, 2007, p. 154). Though there
have been no large studies, small research studies
have shown low numbers of birth defects, fetal
malformations, and abnormalities. Unfortunately,
exposure to chemotherapy during second and third
trimesters heightens the risk for intrauterine growth
restriction and low birth weight. Anorexia, nausea,
and vomiting experienced by the mother in reaction
to the chemotherapy may exacerbate the restricted
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growth of her fetus (Cardonick & Iacobucci, 2004).
Serious dangers from chemotherapy in the first
trimester include risk of miscarriage, major fetal
abnormalities affecting the cardiac, nervous, and
skeletal system, and neural tube defects (Cardonick,
Iacobucci, 2004). Premature labor, intra-uterine
growth restriction, and low birth weight have been
noted with exposure in the second and third trimesters.
Moran et aI. (2007) found that often untreated cancer
poses no risk to a pregnancy unless it proves to be
terminal before the fetus can safely be delivered.
Rarely will any type of cancer be able to metastasize
through the placenta. Depending on the stageofcancer
and time of diagnosis in the pregnancy, postponing
all treatment until the postpartum period may be an
option. Forwomen concerned aboutthe hazards posed
to their baby, this is a popular choice (Dean, 2007).
Review of the Literature
In 200 I, Gelber et aI. investigated maternal and
fetal outcomes in br~st cancer patients compared
to nonpregnant women. The International Breast
Cancer Study Group (IBCSG) studied 94 pregnant
patients at the onset of diagnosis. Using Cox
proportional hazards regression models, they found
a 92% 5 year survival and 86% 10 year survival
rate for pregnant women. This was compared to the
85% and 74% respective survival rates for the non-
pregnant comparison group. The IBCSG concluded
that pregnant patients fared better with their cancer
prognosis, possibly due to a healthy patient bias
within the study or "an antitumor effect of the
pregnancy" (Gelber et aI., 2001). The study size was
small and there was difficulty finding comparison
patients, thus complicating the interpretation of the
data. Out of the 137 pregnancies in conjunction with
a diagnosis of breast cancer, 89 of the pregnancies
resulted in live healthy births, one fetus was delivered
as a stillborn, 12 miscarried, and 33 underwent
therapeutic abortions, and two pregnancies had not
yet delivered. The study concluded that pregnancy
did not adversely affect cancerprognosis regardless of
the treatment prescribed and in fact correlated a better
outcome with pregnant patients (Gelber et aI., 200 I).
In 2007, Sekar & Stone analyzed the effects of
Trastuzumab (Herceptin), a monoclonal antibody
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targeted therapy prescribed for breast cancer. The
effects on the fetus were unknown before the case
study. They reported on one woman diagnosed with
ductal carcinoma during gestation. She received
two cycles after 20 weeks gestation. At her 30 week
ultrasound, the fetus was found to be anhydramniotic.
The fluid reappeared at 33 weeks after the treatment
had been halted for nearly two months. The study
reinforced the dangerous side effects ofTrastuzumab.
Treatment was halted until after delivery by caesarean
section at 36 weeks. The major weakness in this
case study is analyzing the sole patient and lacking
a large subject population (Sekar & Stone, 2007).
Cardonick and Iacobucci (2004) studied the
fetal effects of various classes of chemotherapeutic
agents for breast cancer. Antimetabolites (including
methotrexate, cyclosphosphamide, mercaptopurine,
vincristine,cytarabine,prednisone,and5-fluorouracil)
had adverse events such as spontaneous abortions, low
birth weight, and fatalities related to pancytopenia,
sepsis, and gastroenteritis when given in the first
trimester. Hair loss, inguinal hernia, miscarriage,
and intrauterine fetal death were noted in the first and
second trimesters along with limb malformations.
Alkylating agents produced structural and limb
malformations, esophageal atresia, abnormal inferior
vena cava, and intra-uterine growth restriction.
Sixteen pregnant women were exposed and delivered
at term with no apparent negative effects. Finally,
anthracycline antibiotics were prescribed after the
first trimester with reports of only one terminated
pregnancy and two spontaneous abortions out of 28
total gestations. First trimester exposure problems
included pre-eclampsia, miscarriage, neonatal
neutropenia, sepsis, intra-uterine growth restriction,
and intra-uterine fetal demise. This study, though
limited once again by its retrospective nature and a
limited sample size, reinforced that chemotherapy
is most harmful during the first trimester. Certain
agents carry less risk if postponed until the
second trimester (Cardonick & Iacobucci, 2004).
Influences and Accommodations for Nursing Care
Women who receive simultaneous diagnoses of
pregnancy and breast cancer are often overwhelmed
and confused with their prognosis, the health of their
Schmitt,M.
fetus, and their treatment options. These patients may
have concerns regarding treatment, negative effects
on the baby, or terminating their pregnancy. An
unfavorable prognosis is particularly depressing, as a
woman may need to consider future accommodations
for her child. "Women who have been diagnosed
with breast cancer during pregnancy may require
additional support, both practical and emotional,
and nurses and other healthcare professionals must
be able to meet this demand" (Dean, 2007, p. 48).
Nurses providing care to pregnant breast cancer
patients must ensure specific, thoughtful, and
comprehensive care through an ethically difficult
period. In addition to regular prenatal visits, a
woman will have to coordinate oncology consults,
and high-risk pregnancy doctor appointments.
Nurses should facilitate visits conveniently for the
patient. Communication between different care
providers is essential to offering quality care; nurses
must be conscil'lUs of contacting and interacting
with these other healthcare offices. Nurses must
realize that women have a sense of purpose by
caring a child and this may be a powerful motivation
to fight disease and participate in self-care. With
this idea, nurse must be cognizant of the fear of
life threatening illness and fears of putting their
unborn child at risk. A nurse can suggest outside
support by referring a woman to other professionals,
organizations, support groups, and/or counselors
(Dean, 2007). Since decisions regarding treatment
are case-specific and ethically challenging, the nurse
should offer up to date and current clinical advice,
information, and foresight in regards to trimester of
pregnancy, stage of disease, and options for care.
Another nursing responsibility is offering support
through the grieving process and providing referrals
to counseling and psychological services for women
who have devastating choices, such as termination,
miscarriage, or a prognosis that would not allow
for time to raise her child. Fatigue, nausea, anemia,
and alopecia may continue the first few months after
the pregnancy and affect how a woman can care
for her infant. For women who start chemotherapy
post-partum, nurses may arrange for a home health
nurse to visit the mother and baby periodically.
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Finally, a nursing duty includes reviewing current
literature on this increasingly common scenario and
to seek out evidence-based recommendations in
an effort that the patient receives progressive care.
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